Categories: FinancialNews

Arthrolense and Waldemar Link Form Strategic Agreement to Advance Machine Vision-Enabled Orthopedic Surgery

TORONTO–(BUSINESS WIRE)–Arthrolense, a medical technology company pioneering a machine vision and machine learning-based surgical guidance in orthopedics, announced a new strategic partnership with Waldemar Link GmbH & Co. KG, Germany (“Link”) to introduce their respective technologies to the orthopedic community.


Under the non-exclusive agreement, Arthrolense and Link will collaborate to drive innovation of the Arthrolense 4Divisual guidance system with Link’s primary knee system (LinkSymphoKnee) as well as other advanced knee implant solutions across revision knee indications.

Benefits & Synergies

  • Complementary capabilities: Arthrolense’s real-time surgical visualization and mapping can enhance Link’s knee implant systems to empower surgeons with advanced visual guidance and actionable, patient-specific insights during surgical planning and component placement in primary and revision procedures.
  • Expanded reach & education: Shared surgeon networks can be leveraged to increase market awareness and adoption of these pivotal products and technologies.
  • Patient and surgical benefit: Ultimately, this collaboration aims to reduce surgical variability, improve implant positioning, and support better post-operative outcomes for patients receiving joint arthroplasty.

“We are excited to partner with Link to bring the power of Arthrolense’s advanced technology into everyday surgical practice. This collaboration is a major step forward to deliver Arthrolense’s 4Di system for the benefit of surgeons and patients in the US,” said Oren Gelman, CEO of Arthrolense.

“At Link, our unwavering commitment to innovation is driven by a singular purpose: improving the quality of life for patients worldwide. This partnership with Arthrolense exemplifies how cutting-edge technology can empower surgeons with real-time insights and precision tools—enhancing surgical outcomes and consistency. By integrating our advanced LinkSymphoKnee implant systems with Arthrolense’s visual guidance platform, we are taking a decisive step toward more personalized, predictable, and successful orthopedic procedures,” said Peter Willenborg, CEO of LINK Group.

About Arthrolense

Merging medicine and technology, Arthrolense integrates machine vision with machine learning to empower surgeons with actionable, real-time insights. Leveraging proprietary visualization technology, the patented Arthrolense 4DI visual guidance system delivers precision, personalization, and improved outcomes across a wide range of orthopedic procedures. Arthrolense is redefining decision-making in orthopedic surgery—enabling safer, more predictable outcomes for patients and greater confidence for surgeons.

About Waldemar Link GmbH & Co. KG

Proudly made in Germany and with more than 75 years of history, LINK is a leading provider of innovative orthopedic solutions with an unwavering commitment to quality. With a focused mission on improving patient quality of life, LINK is dedicated to becoming the fastest-growing company in orthopedics. Emphasizing technological advancement and clinical excellence, LINK is devoted to improving standards in orthopedic surgery and advancing the field through innovation and collaboration.

For more information, please visit www.link-ortho.com

LinkSymphoKnee is a trademark of Waldemar Link GmbH & Co. KG

Disclaimer: The Arthrolense device is not commercially available in the United States.

Contacts

Media:

Arthrolense
Kody Smith

k.smith@arthrolense.net

LINK
Dario Lupo

d.lupo@link-ortho.com

Staff

Recent Posts

BeautyStat Daily Radiance Reviews: Don’t Buy Till You’ve Read This!

MIAMI, FL / ACCESS Newswire / December 31, 2025 / Dullness, uneven texture, dryness, and…

2 hours ago

Qiming Venture Partners’ Insilico Medicine Successfully Lists on Hong Kong Stock Exchange

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug…

5 hours ago

Entering the New Year, VARON Strengthens Commitment to Dependable Oxygen Support

NEW YORK, Dec. 30, 2025 /PRNewswire/ -- As the new year begins, it offers a…

5 hours ago

MedMira Reports First Quarter Results FY2026

HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR),…

8 hours ago

Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuff-less 24-hour Ambulatory Blood Pressure Monitor

PETAH TIKVA, Israel & BOCA RATON, Fla.--(BUSINESS WIRE)--#24hourABPM--Biobeat Technologies, Ltd., developer of the first FDA-cleared,…

11 hours ago

KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

11 hours ago